keyword
MENU ▼
Read by QxMD icon Read
search

ASCO

keyword
https://www.readbyqxmd.com/read/28915812/the-economic-burden-of-advanced-gastric-cancer-in-taiwan
#1
Jihyung Hong, Yiling Tsai, Diego Novick, Frank Chi-Huang Hsiao, Rebecca Cheng, Jen-Shi Chen
BACKGROUND: Gastric cancer is one of the leading causes of cancer-related deaths in both sexes worldwide, especially in Eastern Asia. This study aimed to estimate the economic burden of advanced gastric cancer (AGC) in Taiwan. METHODS: The costs of AGC in 2013 were estimated using resource use data from a chart review study (n = 122 with AGC) and national statistics. Annual per-patient costs, where patients' follow-up periods were adjusted for, were estimated with 82 patients who had complete resource use data...
September 16, 2017: BMC Health Services Research
https://www.readbyqxmd.com/read/28900983/-updates-on-adjuvant-therapy-in-gastrointestinal-stromal-tumor
#2
Haibo Qiu, Xiaowei Sun, Zhiwei Zhou
Surgery remains the primary treatment for patients with localized gastrointestinal stromal tumor (GIST), however, even after complete resection of the tumor, there is still a part of patients with tumor recurrence and metastasis. Imatinib, as adjuvant therapy in GIST patients with intermediate and high risk of recurrence, can significantly improve the disease-free survival, but whether it can prolong the overall survival is still unknown. It has reached a consensus that the intermediate and high risk patients should receive adjuvant therapy, but the duration for adjuvant therapy is still under investigation, especially for high-risk patients...
September 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/28892432/patient-clinician-communication-american-society-of-clinical-oncology-consensus-guideline
#3
Timothy Gilligan, Nessa Coyle, Richard M Frankel, Donna L Berry, Kari Bohlke, Ronald M Epstein, Esme Finlay, Vicki A Jackson, Christopher S Lathan, Charles L Loprinzi, Lynne H Nguyen, Carole Seigel, Walter F Baile
Purpose To provide guidance to oncology clinicians on how to use effective communication to optimize the patient-clinician relationship, patient and clinician well-being, and family well-being. Methods ASCO convened a multidisciplinary panel of medical oncology, psychiatry, nursing, hospice and palliative medicine, communication skills, health disparities, and advocacy experts to produce recommendations. Guideline development involved a systematic review of the literature and a formal consensus process. The systematic review focused on guidelines, systematic reviews and meta-analyses, and randomized controlled trials published from 2006 through October 1, 2016...
September 11, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28892092/high-concordance-of-a-closed-system-rt-qpcr-breast-cancer-assay-for-her2-mrna-compared-to-clinically-determined-immunohistochemistry-fluorescence-in-situ-hybridization-and-quantitative-immunofluorescence
#4
Brad E Wasserman, Daniel E Carvajal-Hausdorf, Kenneth Ho, Wendy Wong, Natalie Wu, Victor C Chu, Edwin W Lai, Jodi M Weidler, Michael Bates, Veronique Neumeister, David L Rimm
Historically, mRNA measurements have been tested on several commercially available platforms, but none have gained broad acceptance for assessment of HER2. An mRNA measurement, as a continuous value, has the potential for use in adjudication of the equivocal category. Here we use a real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) assay in a closed, single-use cartridge, automated system. Multiple cores (1 mm in diameter) were retrospectively collected from 80 formalin-fixed paraffin-embedded (FFPE) tissue blocks with invasive breast cancer seen by Yale Pathology Labs between 1998 and 2011...
September 11, 2017: Laboratory Investigation; a Journal of Technical Methods and Pathology
https://www.readbyqxmd.com/read/28881841/efficacy-of-epidermal-growth-factor-receptor-egfr-tyrosine-kinase-inhibitors-tkis-in-targeted-therapy-of-lung-squamous-cell-carcinoma-patients-with-egfr-mutation-a-pooled-analysis
#5
Jingqi Zhuang, Yongfeng Yu, Ziming Li, Shun Lu
PURPOSE: This pooled analysis aims to evaluate the efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in lung squamous cell carcinoma with EGFR mutation. METHODS: Advanced stage (IIIB/IV) lung squamous cell carcinoma patients with EGFR mutations treated with EGFR-TKIs were extracted from the publications searched from the databases of EMBASE, Medline (Ovid SP), Web of Science, Cochrane library, PubMed Publisher, ASCO meeting abstract and Google Scholar before August 2016, or identified from the database of Shanghai Chest Hospital from July 2014 to August 2016...
August 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28877230/decision-impact-and-feasibility-of-different-asco-recommended-biomarkers-in-early-breast-cancer-prospective-comparison-of-molecular-marker-endopredict-and-protein-marker-upa-pai-1
#6
Johannes Ettl, Evelyn Klein, Alexander Hapfelmeier, Kirsten Grosse Lackmann, Stefan Paepke, Christoph Petry, Katja Specht, Laura Wolff, Heinz Höfler, Marion Kiechle
BACKGROUND: Adjuvant therapy decisions in early breast cancer are based on accurate risk assessment. Urokinase plasminogen activator (uPA) and plaminogen activator inhibitor-1 (PAI-1) have been the first biomarkers in hormone receptor (HR) positive breast cancer to reach highest level of evidence. The EndoPredict test (EPclin) combines gene expression information with nodal status and tumor size. The aim of this prospective study was to compare uPA/PAI-1 and EPclin as prognostic biomarkers with regard to feasibility, risk stratification and impact on adjuvant therapy recommendation...
2017: PloS One
https://www.readbyqxmd.com/read/28877070/effects-of-hydrochloric-acid-and-formic-acid-decalcification-on-breast-tumor-biomarkers-and-her2-fluorescence-in-situ-hybridization
#7
Beth Z Clark, Jennifer M Yoest, Agnieszka Onisko, David J Dabbs
Biomarker analysis of metastatic breast carcinoma (MBC) is routinely recommended by ASCO/CAP guidelines, and establishing a diagnosis of MBC often requires immunohistochemistry (IHC). The reliability of breast tumor biomarkers and breast-specific markers on decalcified tissues has not been extensively studied. We performed IHC studies on breast tumors exposed to hydrochloric acid (HCl) and formic acid (FA) decalcification solutions, and HER2 fluorescence in situ hybridization on a subset of these tumors to establish a protocol for handling bone specimens with suspicion for MBC...
September 4, 2017: Applied Immunohistochemistry & Molecular Morphology: AIMM
https://www.readbyqxmd.com/read/28871570/osteoporosis-drug-treatment-duration-and-management-after-discontinuation-a-position-statement-from-the-svgo-asco
#8
Christian Meier, Brigitte Uebelhart, Bérengère Aubry-Rozier, Martin Birkhäuser, Heike A Bischoff-Ferrari, Diana Frey, Reto W Kressig, Olivier Lamy, Kurt Lippuner, Petra Stute, Norbert Suhm, Serge Ferrari
Antiosteoporotic drugs are recommended in patients with fragility fractures and in patients considered to be at high fracture risk on the basis of clinical risk factors and/or low bone mineral density. As first-line treatment most patients are started with an antiresorptive treatment, i.e. drugs that inhibit osteoclast development and/or function (bisphosphonates, denosumab, oestrogens or selective oestrogen receptor modulators). In the balance between benefits and risks of antiresorptive treatment, uncertainties remain regarding the optimal treatment duration and the management of patients after drug discontinuation...
September 5, 2017: Swiss Medical Weekly
https://www.readbyqxmd.com/read/28863804/investigation-of-a-gene-signature-to-predict-response-to-immunomodulatory-derivatives-for-patients-with-multiple-myeloma-an-exploratory-retrospective-study-using-microarray-datasets-from-prospective-clinical-trials
#9
Manisha Bhutani, Qing Zhang, Reed Friend, Peter M Voorhees, Lawrence J Druhan, Bart Barlogie, Pieter Sonneveld, Gareth J Morgan, James T Symanowski, Belinda R Avalos, Edward A Copelan, Saad Z Usmani
BACKGROUND: Immunomodulatory derivatives (IMiDs), along with proteasome inhibitors, are key components of treatment regimens for multiple myeloma. Nonetheless, outcomes vary among treated individuals. Drug-specific gene-expression profile (GEP) signatures that aid the prediction of favourable and unfavourable outcomes can provide patients with the most effective therapy for their individual disease. We aimed to develop and validate a gene expression signature to suggest which patients would benefit most from IMiD-based therapies...
September 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28863776/a-change-in-the-study-evaluation-paradigm-reveals-that-larynx-preservation-compromises-survival-in-t4-laryngeal-cancer-patients
#10
Gerhard Dyckhoff, Peter K Plinkert, Heribert Ramroth
BACKGROUND: Larynx preservation (LP) is recommended for up to low-volume T4 laryngeal cancer as an evidence-based treatment option that does not compromise survival. However, a reevaluation of the current literature raises questions regarding whether there is indeed reliable evidence to support larynx preservation for T4 tumor patients. METHODS: In an observational cohort study of 810 laryngeal cancer patients, we evaluated the outcomes of all T4 tumor patients treated with primary chemo-radiotherapy (CRT) or primary radiotherapy alone (RT) compared with upfront total laryngectomy followed by adjuvant (chemo)radiotherapy (TL + a[C]RT)...
September 1, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28862039/application-of-the-american-society-of-clinical-oncology-frameworks-to-compare-tyrosine-kinase-inhibitors-used-in-first-line-treatment-of-metastatic-renal-cell-carcinoma-had-we-solved-the-mystery
#11
Sherif Hassanien Ahmed, Noha Elbaghdady, Mohamed Alorabi
The approval of multiple biological therapies as a first line treatment for metastatic renal cell carcinoma (mRCC) in the last decade have made the selection of the best treatment between these drugs, especially tyrosine kinase inhibitors (TKIs), a great challenge to oncologists and patients. The four TKIs recommended by the National Comprehensive Cancer Network guidelines in this setting have a relatively similar mechanism of action and analogical adverse events. Areas covered: In this article, the two published American Society of Clinical Oncology frameworks are applied to calculate the net health benefits of the four TKIs used as the first line in mRCC and this was balanced against their monthly cost...
September 7, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28861637/impact-of-repeat-her2-testing-after-initial-equivocal-her2-fish-results-using-2013-asco-cap-guidelines
#12
Fang-Ping Xu, Kun Wang, Jie Xu, Jie Chen, Yi-Fang Zhang, Hong-Mei Wu, Ming-Hui Zhang, Xiao-Xu Long, Xin-Lan Luo, Ke-Ping Zhang, Dan-Yi Lin, Yan-Hui Liu
PURPOSE: The updated 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing have made some major changes in HER2 fluorescence in situ hybridization (FISH) interpretation criteria with additional FISH equivocal cases. Repeat HER2 testing is recommended after initial HER2 FISH equivocal results; however, little is known about its impact on final HER2 status. The aim of this study is to investigate whether reflex test clarifies HER2 status, and to characterize clinicopathological features of the newly defined HER2 equivocal group...
August 31, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28834684/discussing-health-care-expenses-in-the-oncology-clinic-analysis-of-cost-conversations-in-outpatient-encounters
#13
Wynn G Hunter, S Yousuf Zafar, Ashley Hesson, J Kelly Davis, Christine Kirby, Jamison A Barnett, Peter A Ubel
PURPOSE: ASCO identified oncologist-patient conversations about cancer costs as an important component of high-quality care. However, limited data exist characterizing the content of these conversations. We sought to provide novel insight into oncologist-patient cost conversations by determining the content of cost conversations in breast cancer clinic visits. METHODS: We performed content analysis of transcribed dialogue from 677 outpatient appointments for breast cancer management...
August 23, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28831443/survey-of-implementation-of-antiemetic-prescription-standards-in-indian-oncology-practices-and-its-adherence-to-the-american-society-of-clinical-oncology-antiemetic-clinical-guideline
#14
Vijay Patil, Vanita Noronha, Amit Joshi, Purvish Parikh, Atanu Bhattacharjee, Santam Chakraborty, Sunny Jandyal, Vamshi Muddu, Anant Ramaswamy, K Govinda Babu, Nilesh Lokeshwar, Sachin Hingmire, Nikhil Ghadyalpatil, Shripad Banavali, Kumar Prabhash
PURPOSE: Adherence to international antiemetic prophylaxis guidelines like those of ASCO can result in better control of chemotherapy-induced nausea and vomiting; however, the extent of implementation of such guidelines in India is unknown. Therefore, this survey was planned. METHODS: This study was an anonymized cross-sectional survey approved by the ethics committee. Survey items were generated from the clinical questions given in the ASCO guidelines. The survey was disseminated through personal contacts at an oncology conference and via e-mail to various community oncology centers across India...
August 2017: Journal of Global Oncology
https://www.readbyqxmd.com/read/28820270/second-line-treatment-options-for-pancreatic-cancer
#15
Frank C Passero, Muhammad Wasif Saif
ABTRACT Introduction: Patients with advanced pancreatic cancer (APC) refractory to first-line therapy have a dismal prognosis and limited therapeutic options, with only one option consisting of nanoliposomal irinotecan in combination with fluorouracil and folinic acid which was approved by FDA based upon results of the phase III NAPOLI-1 study. Areas covered: We performed a literature search for relevant published clinical trials, abstracts of trials in progress and ongoing or planned trials for the second line treatment of APC using Pubmed...
August 18, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28806116/systemic-therapy-for-stage-iv-non-small-cell-lung-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update
#16
Nasser Hanna, David Johnson, Sarah Temin, Sherman Baker, Julie Brahmer, Peter M Ellis, Giuseppe Giaccone, Paul J Hesketh, Ishmael Jaiyesimi, Natasha B Leighl, Gregory J Riely, Joan H Schiller, Bryan J Schneider, Thomas J Smith, Joan Tashbar, William A Biermann, Gregory Masters
Purpose Provide evidence-based recommendations updating the 2015 ASCO guideline on systemic therapy for patients with stage IV non-small-cell lung cancer (NSCLC). Methods The ASCO NSCLC Expert Panel made recommendations based on a systematic review of randomized controlled trials from February 2014 to December 2016 plus the Cancer Care Ontario Program in Evidence-Based Care's update of a previous ASCO search. Results This guideline update reflects changes in evidence since the previous guideline update. Fourteen randomized controlled trials provide the evidence base; earlier phase trials also informed recommendation development...
August 14, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28801821/-optimal-margins-for-breast-conserving-surgery-with-whole-breast-irradiation-in-ductal-carcinoma-in-situ-results-of-the-astro-asco-and-sso-consensus-guideline
#17
Rainer Souchon
No abstract text is available yet for this article.
August 10, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/28789707/checkpoint-inhibitors-in-melanoma-and-early-phase-development-in-solid-tumors-what-s-the-future
#18
EDITORIAL
Paolo A Ascierto, Grant A McArthur
Anti-programmed death (PD)-1 and PD-ligand (L)-1 checkpoint inhibitors have revolutionized the therapy of several cancers. Immunotherapy of cancer can offer long-term durable benefit to patients, is active regardless of tumour histology, has a unique immune-related safety profile, and can be used in combination with other cancer treatments. In addition, recent research has shown that immune-based therapy can be used as adjuvant therapy, that outcomes may be influenced by dose, and that clinical activity is observed in patients with brain metastases...
August 8, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/28783425/choosing-wisely-in-oncology-are-we-ready-for-value-based-care
#19
Gabrielle Rocque, Douglas W Blayney, Mohammad Jahanzeb, August Knape, Merry Jennifer Markham, Trang Pham, Jeremy Shelton, Preeti Sudheendra, Tracey Evans
INTRODUCTION: In 2012, ASCO created the Top Five Choosing Wisely (CW) list of low-value tests and procedures for which there is little evidence of benefit. ASCO's Quality Oncology Practice Initiative, an oncologist-led practice-based quality assessment program, includes measures on the basis of these recommendations. METHODS: CW test measures from spring and fall 2013, spring 2014, and spring 2015 were evaluated for concordance rates, change in the concordance over time, and variability by practice characteristics...
August 7, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28769123/capecitabine-5-fluorouracil-and-s-1-based-regimens-for-previously-untreated-advanced-oesophagogastric-cancer-a-network-meta-analysis
#20
Emil Ter Veer, Lok Lam Ngai, Gert van Valkenhoef, Nadia Haj Mohammad, Maarten C J Anderegg, Martijn G H van Oijen, Hanneke W M van Laarhoven
As evidence is inconsistent and based on either isolated Asian or Western studies, we conducted a network meta-analysis (NMA) to examine efficacy and safety of 5-FU (5-fluorouracil), capecitabine and S-1-based first-line treatment of advanced esophagogastric cancer in Asian and Western patients. Medline, EMBASE, CENTRAL and conferences ASCO and ESMO were searched up to January 2016 for randomized-controlled-trials comparing 5-FU, capecitabine or S-1-based regimens with equal chemotherapy backbones. Direct and indirect data for overall survival (OS) and progression-free-survival (PFS) were combined on the Hazard Ratio (HR)-scale using random-effects NMA and calculated as combined HRs and 95%credible intervals (95%CrI)...
August 2, 2017: Scientific Reports
keyword
keyword
33466
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"